Related Experiment Video

Updated: Feb 13, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

429

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management

Xilin Sun1,2,3, Zunyu Xiao1, Gongyan Chen4

  • 1Molecular Imaging Research Center, Harbin Medical University (MIRC), Harbin, Heilongjiang 150028, China.

Science Translational Medicine
|March 9, 2018
PubMed

Insights

A new PET tracer, 18F-MPG, enables noninvasive imaging of EGFR mutations in non-small cell lung cancer (NSCLC). This tracer helps identify patients who will respond to EGFR tyrosine kinase inhibitor (TKI) therapy, improving treatment strategies.

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Tumor heterogeneity and dynamic changes in epidermal growth factor receptor (EGFR) mutation status complicate effective EGFR tyrosine kinase inhibitor (TKI) treatment for non-small cell lung cancer (NSCLC).
  • Accurate, real-time EGFR profiling is crucial for advancing precision medicine in NSCLC clinical trials.

Purpose of the Study:

  • To develop and evaluate a novel positron emission tomography (PET) tracer, 18F-MPG, for noninvasive imaging and quantification of EGFR-activating mutation status in NSCLC.
  • To assess the feasibility of 18F-MPG PET for identifying NSCLC patients who are sensitive to EGFR-TKI therapy and for monitoring treatment efficacy.

Main Methods:

  • Synthesis and characterization of 18F-MPG, a PET tracer with high specificity for activating EGFR mutant kinase.
  • Evaluation of 18F-MPG PET in preclinical NSCLC models and in a clinical study involving 75 NSCLC patients with primary and metastatic tumors.
  • Correlation analysis between 18F-MPG uptake and EGFR mutation status, and comparison of 18F-MPG PET/CT results with tissue biopsy findings.

Main Results:

  • In NSCLC animal models, 18F-MPG uptake strongly correlated with activating EGFR mutation status (R² = 0.9050).
  • Clinical studies showed an 84.29% concordance between 18F-MPG PET/CT and tissue biopsy for detecting EGFR activation in NSCLC patients.
  • Patients with 18F-MPG PET/CT SUVmax ≥2.23 exhibited significantly better response rates (81.58% vs. 6.06%) and longer progression-free survival (348 days vs. 183 days) to EGFR-TKIs compared to those with SUVmax <2.23.

Conclusions:

  • 18F-MPG PET/CT is a powerful tool for precise, noninvasive quantification of EGFR-activating mutation status in NSCLC patients.
  • This imaging approach can effectively identify patients likely to respond to EGFR-TKIs, guiding personalized treatment strategies.
  • 18F-MPG PET/CT shows promise for monitoring the efficacy of EGFR-TKI therapy in NSCLC.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.4K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.6K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.0K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
215
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K